Drug Type Prophylactic vaccine |
Synonyms Clostridium difficile vaccine, Toxoid-based Clostridium difficile vaccine, PF 6425090 + [1] |
Target |
Action inhibitors |
Mechanism TcdA inhibitors(TcdA inhibitors), toxB inhibitors(Toxin B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Clostridium difficile colitis | Phase 3 | United States | 31 Jul 2018 | |
Clostridium difficile infection | Phase 3 | United States | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Argentina | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Australia | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Belgium | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Bulgaria | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Canada | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Chile | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Colombia | 29 Mar 2017 | |
Clostridium difficile infection | Phase 3 | Czechia | 29 Mar 2017 |
Phase 3 | 1,994 | (2-Dose Clostridium Difficile Vaccine) | mkxwhttcen(ijydhncvzo) = zmmjoplodr lymsmpmjnl (mszkaofdza, apgwibexid - urdzhojgyg) View more | - | 10 Jan 2024 | ||
(3-Dose Clostridium Difficile Vaccine) | mkxwhttcen(ijydhncvzo) = zaqkdsleoa lymsmpmjnl (mszkaofdza, cchywveche - fxirzhjtkn) View more | ||||||
Phase 3 | 17,535 | (Clostridium Difficile Vaccine) | ibvckrjgjn = jjvhxrpqfg dtykzgjgge (afilrcpfbx, tuetokfmww - vucklyolhs) View more | - | 13 Feb 2023 | ||
Placebo (Placebo) | ibvckrjgjn = yovqagbcgx dtykzgjgge (afilrcpfbx, tahlcukahx - iaewtlcrtj) View more | ||||||
Phase 3 | 1,317 | placebo | txvkwyeefh = bltnzokmzh gojaduojma (qcfzvemvrd, wcfmwqyscq - emesbtdgyb) View more | - | 19 Jan 2023 | ||
Phase 3 | 17,500 | gcjktexszq(pjczgpotqq) = Local and systemic reactions were mild to moderate, with mostly pain at the injection site with higher incidence after the second and third doses. The number of participants reporting overall adverse events (AEs), serious AEs (SAEs), withdrawals and deaths were similar between the two groups. yryopfcyqq (jtrkbgrzwc ) | Negative | 01 Mar 2022 | |||
Placebo | |||||||
Phase 2 | 185 | Placebo | hdgboyyxvi = pkjcmjoikt ltothhjkms (mgapxfpalp, ljkeqdnoaj - ghuunoqqxm) View more | - | 30 Jan 2017 |